-
1.发明申请公开(公告)号：US20090215639A1
公开(公告)日：2009-08-27
申请号：US11912568
申请日：2006-04-26
申请人： Roberto Crea , Arvind Rajpal , Guido Cappuccilli , Toshihiko Takeuchi , Ramesh Bhatt , Randy Shen
发明人： Roberto Crea , Arvind Rajpal , Guido Cappuccilli , Toshihiko Takeuchi , Ramesh Bhatt , Randy Shen
CPC分类号： C07K16/00 , C07K2317/72 , C07K2319/30 , C07K2319/33 , C12N15/1051 , C12N15/1086
摘要： A method for generating human IgG1 antibodies with enhanced Fc effector function is disclosed. In practicing the method, an IgG1 Fc look-through mutagenesis (LTM) coding library directed at four receptor-contact regions of the Fc CH2 portion of in human IgG1 Fc is expressed in a system in which the mutated Fc fragments are displayed on the surfaces of the expression cells. The fragments are then screened for altered binding affinity to a selected Fc receptor or other Fc-binding protein. The selected mutations may be used, in turn, to guide the selection of multiple substitutions in the construction of a walk-through mutation (WTM) library, for generating additional Fc fragment mutations with desired binding properties. The antibodies so produced have a variety of therapeutic and diagnostic applications.
摘要翻译： 公开了产生具有增强的Fc效应子功能的人IgG1抗体的方法。 在实施该方法中，针对人IgG1 Fc中的Fc CH2部分的四个受体 - 接触区域的IgG1 Fc直通诱变（LTM）编码文库在其中突变的Fc片段显示在表面上的系统中表达 的表达细胞。 然后筛选片段以改变与选定的Fc受体或其它Fc结合蛋白的结合亲和力。 可以使用选定的突变来指导在构建穿越突变（WTM）文库中的多个取代的选择，以产生具有期望的结合性质的另外的Fc片段突变。 所产生的抗体具有多种治疗和诊断应用。
-
2.发明申请METHOD OF PRODUCING HUMAN IGG ANTIBODIES WITH ENHANCED EFFECTOR FUNCTIONS 审中-公开生产具有增强效应功能的人IGG抗体的方法公开(公告)号：US20120107871A1
公开(公告)日：2012-05-03
申请号：US13268149
申请日：2011-10-07
申请人： Roberto Crea , Guido Cappuccilli , Toshihiko Takeuchi , Arvind Rajpal , Ramesh Bhatt , Randy Shen
发明人： Roberto Crea , Guido Cappuccilli , Toshihiko Takeuchi , Arvind Rajpal , Ramesh Bhatt , Randy Shen
CPC分类号： C07K16/00 , C07K2317/72 , C07K2319/30 , C07K2319/33 , C12N15/1051 , C12N15/1086
摘要： A method for generating human IgG1 antibodies with enhanced Fc effector function is disclosed. In practicing the method, an IgG1 Fc look-through mutagenesis (LTM) coding library directed at four receptor-contact regions of the Fc CH2 portion in human IgG1. Fc is expressed in a system in which the mutated Fc fragments are displayed on the surfaces of the expression cells. The fragments are then screened for altered binding affinity to a selected Fc receptor or other Fc-binding protein. The selected mutations may be used, in turn, to guide the selection of multiple substitutions in the construction of a walk-through mutation (WTM) library, for generating additional Fc fragment mutations with desired binding properties. The antibodies so produced have a variety of therapeutic and diagnostic applications.
摘要翻译： 公开了产生具有增强的Fc效应子功能的人IgG1抗体的方法。 在实施该方法中，针对人IgG1中Fc-CH2部分的四个受体 - 接触区域的IgG1 Fc直通诱变（LTM）编码文库。 Fc在其中突变的Fc片段显示在表达细胞的表面上的系统中表达。 然后筛选片段以改变与选定的Fc受体或其它Fc结合蛋白的结合亲和力。 可以使用选定的突变来指导在构建穿越突变（WTM）文库中的多个取代的选择，以产生具有期望的结合性质的另外的Fc片段突变。 所产生的抗体具有多种治疗和诊断应用。
-
公开(公告)号：US11674240B2
公开(公告)日：2023-06-13
申请号：US11571710
申请日：2005-07-06
CPC分类号： C40B40/08 , C07K16/00 , C07K2317/21 , C07K2317/565 , C07K2317/567 , C07K2317/622
摘要： Universal antibody libraries are described which are synthetic and derived from expressed human antibody sequences selected accordingly to certain criteria, for example, that the sequences are derived from naturally-occurring antibodies expressed in response to a certain antigen class (e.g., small molecule, polysaccharide, peptide, or protein) and having CDR regions engineered for optimal diversity. Methods for making and screening such libraries for isolating therapeutics suitable for treating disease are also disclosed.
-
公开(公告)号：US20110245108A1
公开(公告)日：2011-10-06
申请号：US11571710
申请日：2005-07-06
CPC分类号： C07K16/00 , C07K2317/21 , C07K2317/565 , C07K2317/567 , C07K2317/622
摘要： Universal antibody libraries are described which are synthetic and derived from expressed human antibody sequences selected accordingly to certain criteria, for example, that the sequences are derived from naturally-occurring antibodies expressed in response to a certain antigen class (e.g., small molecule, polysaccharide, peptide, or protein) and having CDR regions engineered for optimal diversity. Methods for making and screening such libraries for isolating therapeutics suitable for treating disease are also disclosed.
摘要翻译： 描述了通用抗体文库，其是合成的，并且衍生自相应于某些标准的表达的人抗体序列，例如，所述序列衍生自响应某一抗原类别（例如小分子，多糖， 肽或蛋白质）并且具有被设计用于最佳多样性的CDR区域。 还公开了用于制备和筛选用于分离适合治疗疾病的治疗剂的文库的方法。
-
公开(公告)号：US20060024308A1
公开(公告)日：2006-02-02
申请号：US11176525
申请日：2005-07-06
IPC分类号： C07K16/24 , A61K39/395
CPC分类号： C07K16/241 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/76 , C07K2317/92
摘要： An isolated human anti-TNF-α antibody, or antigen-binding portion thereof, containing at least one high-affinity VL or VH antibody chain that is effective, when substituted for the corresponding VL or VH chain of the anti-TNF-α scFv antibody having sequence SEQ ID NO: 1, to bind to human TNF-α with a Koff rate constant that is at least 1.5 fold lower than that of the antibody having SEQ ID NO: 1, when determined under identical conditions.
摘要翻译： 包含至少一种高亲和力V L或V H H抗体链的分离的人抗TNF-α抗体或其抗原结合部分，其有效，当 代替具有序列SEQ ID NO：1的抗TNF-αscFv抗体的相应的V L或V H H链与人TNF-α结合， 当相同条件下测定时，其比例为具有SEQ ID NO：1的抗体的至少1.5倍的速率常数。
-
公开(公告)号：US08640568B2
公开(公告)日：2014-02-04
申请号：US12554065
申请日：2009-09-04
IPC分类号： F16C1/10
摘要： A bicycle shift control device is provided with a shifter housing, a gear shifting mechanism, a shift operating member, and a shift switching arrangement. The gear shifting mechanism is disposed in the shifter housing with the gear shifting mechanism having a plurality of operating positions. The shift operating member is movable with respect to the shifter housing to operate the gear shifting mechanism. The shift switching arrangement includes a restricting member movably mounted with respect to the shifter housing between a non-shift restricting position and a shift restricting position. The gear shifting mechanism moves in a first set of the operating positions when the restricting member is in the non-shift restricting position, and moves in a second set of the operating positions that are different from the first set of the operating positions when the restricting member is in the shift restricting position.
摘要翻译： 一种自行车变速控制装置设置有变速器壳体，变速机构，变速操作构件和变速切换装置。 变速机构设置在变速器壳体中，变速机构具有多个操作位置。 变速操作构件可相对于换档器壳体移动以操作变速机构。 变速切换装置包括限制构件，其相对于变速器壳体可移动地安装在非换档限制位置和换档限制位置之间。 当限制构件处于非换档限制位置时，变速机构在第一组操作位置中移动，并且当限制构件处于非换挡限制位置时，在与第一组操作位置不同的第二组操作位置中移动 会员处于班次限制位置。
-
公开(公告)号：US20110056319A1
公开(公告)日：2011-03-10
申请号：US12554065
申请日：2009-09-04
摘要： A bicycle shift control device is provided with a shifter housing, a gear shifting mechanism, a shift operating member, and a shift switching arrangement. The gear shifting mechanism is disposed in the shifter housing with the gear shifting mechanism having a plurality of operating positions. The shift operating member is movable with respect to the shifter housing to operate the gear shifting mechanism. The shift switching arrangement includes a restricting member movably mounted with respect to the shifter housing between a non-shift restricting position and a shift restricting position. The gear shifting mechanism moves in a first set of the operating positions when the restricting member is in the non-shift restricting position, and moves in a second set of the operating positions that are different from the first set of the operating positions when the restricting member is in the shift restricting position.
摘要翻译： 一种自行车变速控制装置设置有变速器壳体，变速机构，变速操作构件和变速切换装置。 变速机构设置在变速器壳体中，变速机构具有多个操作位置。 变速操作构件可相对于换档器壳体移动以操作变速机构。 变速切换装置包括限制构件，其相对于变速器壳体可移动地安装在非换档限制位置和换档限制位置之间。 当限制构件处于非换档限制位置时，变速机构在第一组操作位置中移动，并且当限制构件处于非换挡限制位置时，在与第一组操作位置不同的第二组操作位置中移动 会员处于班次限制位置。
-
公开(公告)号：USD609252S1
公开(公告)日：2010-02-02
申请号：US29304155
申请日：2008-02-26
-
公开(公告)号：US07227009B2
公开(公告)日：2007-06-05
申请号：US11253869
申请日：2005-10-18
IPC分类号： C12N15/11
CPC分类号： C12N9/6408
摘要： This invention provides a novel membrane-type serine protease (designated MT-SP1) elevated expression of which is associated with cancer. In one embodiment, this invention provides a method obtaining a prognosis or of detecting or staging a cancer in an organism. The method involves providing a biological sample from the organism and detecting the level of a membrane type serine protease 1 (MT-SP1) in the sample, where an elevated level of the membrane-type serine protease, as compared to the level of the protease in a biological sample from a normal healthy organism indicates the presence or stage of the cancer.
摘要翻译： 本发明提供了与癌症相关的新型膜型丝氨酸蛋白酶（称为MT-SP1），其表达升高。 在一个实施方案中，本发明提供了获得预后或在生物体中检测或分期癌症的方法。 该方法包括从生物体提供生物样品，并检测样品中膜型丝氨酸蛋白酶1（MT-SP1）的水平，其中与蛋白酶水平相比，膜型丝氨酸蛋白酶水平升高 来自正常健康生物体的生物样品表明癌症的存在或阶段。
-
公开(公告)号：US07030231B1
公开(公告)日：2006-04-18
申请号：US09410362
申请日：1999-09-30
IPC分类号： C12N15/11
CPC分类号： C12N9/6408
摘要： This invention provides a novel membrane-type serine protease (designated MT-SP1) elevated expression of which is associated with cancer. In one embodiment, this invention provides a method obtaining a prognosis or of detecting or staging a cancer in an organism. The method involves providing a biological sample from the organism and detecting the level of a membrane type serine protease 1 (MT-SP1) in the sample, where an elevated level of the membrane-type serine protease, as compared to the level of the protease in a biological sample from a normal healthy organism indicates the presence or stage of the cancer.
摘要翻译： 本发明提供了与癌症相关的新型膜型丝氨酸蛋白酶（称为MT-SP1），其表达升高。 在一个实施方案中，本发明提供了获得预后或在生物体中检测或分期癌症的方法。 该方法包括从生物体提供生物样品，并检测样品中膜型丝氨酸蛋白酶1（MT-SP1）的水平，其中与蛋白酶水平相比，膜型丝氨酸蛋白酶水平升高 来自正常健康生物体的生物样品表明癌症的存在或阶段。
-
-
-
-
-
-
-
-
-
搜索结果
45 条记录 (耗时 0.035 秒)
